Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anticipated administration of GM-CSF in the treatment of non small cell lung cancer
Autore:
Erkisi, M; Erkurt, E; Zeren, H; Tunali, C; Kocabas, A; Burgut, R;
Indirizzi:
Cukurova Univ, Sch Med, Dept Med Oncol, Adana, Turkey Cukurova Univ Adana Turkey Univ, Sch Med, Dept Med Oncol, Adana, Turkey
Titolo Testata:
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
fascicolo: 3, volume: 20, anno: 2001,
pagine: 345 - 349
SICI:
0392-9078(200109)20:3<345:AAOGIT>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING-FACTOR; RANDOMIZED TRIAL; DOUBLE-BLIND; PHASE-III; CHEMOTHERAPY; PLACEBO; CYCLOPHOSPHAMIDE; ADJUNCT;
Keywords:
chemotherapy; GM-CSF; non small cell lung cancer; radiotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Erkurt, E Cukurova Univ, Fac Med, Dept Radiat Oncol, TR-01330 Adana, Turkey Cukurova Univ Adana Turkey TR-01330 ol, TR-01330 Adana, Turkey
Citazione:
M. Erkisi et al., "Anticipated administration of GM-CSF in the treatment of non small cell lung cancer", J EXP CL C, 20(3), 2001, pp. 345-349

Abstract

The purpose of this study was to verify the kinetic response of the human marrow myeloid progenitor cells to the short term use of GM-CSF and its impact on the therapeutic activity of this three-drug cisplatinum containing regimen in non small cell lung cancer (NSCLC). Sixty patients with stage III-B and IV NSCLC were randomised to receive GM-CSF for 3 days, five days prior to the onset of chemotherapy. The chemotherapy regimen consisted of Mitomycin-C: 6 mg/m(2) on day one, Ifosfamide: 2000 mg/m(2) days 1 to 3, Mesna: 2000 mg/m(2) days 1 to 3, Cisplatinum: 30 mg/m2 days I to 3, and was repeated every 4 weeks. All the patients received 30-50 Gy of radiotherapy to the primary and/or metastatic sites. There were positive correlations between stage of the disease, chemosensitivity of the tumor, number of chemotherapy cycles and overall survival (p=0.000). Administration of GM-CSF was an independent prognostic parameter in locally advanced and metastatic disease (p=0.041). In the GM-CSF receiving arm more courses could be given (117 versus 99, p=0.0415), and less courses were postponed (6 versus 22). In this arm, the mean of granulocyte nadir was higher (p=0.033) and mean time to granulocyte recovery became shorter (p=0.001) as the number of chemotherapy cycles increased. It was concluded that, dose intensification with GM-CSF prophylaxis is benefical in increasing the treatment tolerability by decreasing the intensityof granulocytopenia as well as providing rapid recovery.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 19:53:54